Diffuse Large B-Cell Lymphoma- Global Clinical Trial Landscape

Diffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of cases of non-Hodgkin lymphoma worldwide. In 2022, DLBCL affected approximately 194,000 people globally, with the highest prevalence in Asia, followed by Europe and North America. The treatment landscape for this disease includes systemic therapies tailored to disease progression and patient factors. Standard first-line regimens, such as R-CHOP and Pola-R-CHP, are recommended by guidelines from NCCN and CSCO. Relapsed or refractory cases often require advanced treatments like CAR-T cell therapy or bispecific antibodies, such as Glofitamab. Emerging therapies—Mosunetuzumab and Selinexor—are in phase III trials, demonstrating continued innovation in DLBCL treatment.

Since 2019, over 1,500 diffuse large B-cell lymphoma clinical trials have launched worldwide, with Asia-Pacific leading in trial volume. Key research hubs include China, the U.S., Spain, and France. As a leading CRO, Novotech has partnered with biotech companies to support oncology trials, leveraging its experience in immuno-oncology and advanced therapies. In this e-book, you will learn more about advancements in DLBCL research and personalized care strategies.